Clinical Endocannabinoid Deficiency (CECD)
Definition - What does Clinical Endocannabinoid Deficiency (CECD) mean?
The body’s endocannabinoid system (ECS) is the largest neurotransmitter in the human body. It is made up of a burgeoning collection of cell receptors and molecules that all work together to be the body’s messengers. Too much or too little signaling of the ECS receptors and molecules leads to disease.
In 2004, Dr. Ethan Russo coined the term Clinical Endocannabinoid Deficiency (CECD) to better explain disorders that are caused when there is not enough signally of the ECS system. Disorders such as chronic migraines, irritable bowel syndrome, and fibromyalgia are all thought to be caused from CECD. The use of cannabis is being studied to treat Clinical Endocannabinoid Deficiency since it appears that the cannabinoids in cannabis help increase the signals of the ECS system and might relieve a variety of CECD conditions such as migraines, fibromyalgia, or irritable bowel syndrome.
Hydrolife explains Clinical Endocannabinoid Deficiency (CECD)
Cannabinoids found in cannabis may help substitute the depleted endocannabinoid system that is found in Clinical Endocannabinoid Deficiency. Sufferers of Clinical Endocannabinoid Deficiency all exhibit a few characteristics such as elevated levels of a serotonin during a migraine attack. The cannabinoids in cannabis appear to lower the levels of serotonin and help reduce the frequency and severity of migraines.
With fibromyalgia, it is believed that a deficiency in serotonin sparks an attack. Irritable bowel syndrome has also been linked to the body’s serotonin levels. Researchers are currently studying the links between CECD and cannabis to better understand their ties and discover more treatment options.